How to buy Replimune Group stock (REPL)

Replimune Group is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.50 – an increase of 7.2% over the previous week. Replimune Group employs 331 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Replimune Group stock

Buy Replimune Group stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Replimune Group stock price (NASDAQ: REPL)

Use our graph to track the performance of REPL stocks over time.

Replimune Group shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$12.50
52-week range	$4.92 - $17.00
50-day moving average more info button	$12.17
200-day moving average more info button	$9.54
Wall St. target price	$16.88
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.04

Is it a good time to buy Replimune Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Replimune Group price performance over time

Historical closes compared with the close of $12.34 from 2024-12-23

1 week (2024-12-18)	5.83%
1 month (2024-11-25)	-6.94%
3 months (2024-09-25)	11.47%
6 months (2024-06-25)	39.91%

1 year (2023-12-22)	51.41%
2 years (2022-12-23)	-53.90%
3 years (2021-12-23)	28.81
5 years (2019-12-24)	15.82

Replimune Group financials

Gross profit TTM	$0
Return on assets TTM	-27.07%
Return on equity TTM	-50.32%
Profit margin	0%
Book value	$5.58
Market Capitalization more info button	$897.3 million

TTM: trailing 12 months

Replimune Group share dividends

We're not expecting Replimune Group to pay a dividend over the next 12 months.

Replimune Group share price volatility

Over the last 12 months, Replimune Group's shares have ranged in value from as little as $4.92 up to $17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 1.193. This would suggest that Replimune Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Replimune Group overview

Replimune Group, Inc. , a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

What percentage of Replimune Group is owned by insiders or institutions?
Currently 4.196% of Replimune Group shares are held by insiders and 92.169% by institutions. How many people work for Replimune Group?
Latest data suggests 331 work at Replimune Group. When does the fiscal year end for Replimune Group?
Replimune Group's fiscal year ends in March. Where is Replimune Group based?
Replimune Group's address is: 500 Unicorn Park Drive, Woburn, MA, United States, 01801 What is Replimune Group's ISIN number?
Replimune Group's international securities identification number is: US76029N1063 What is Replimune Group's CUSIP number?
Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106